Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2019 | Pages:
161 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global antisense and RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, according to a new report by Grand View Research, Inc., recording a 7.5% CAGR during the forecast period. Rising instances of external funding to conduct clinical studies pertaining to introduction of novel drug moieties plays a vital role in the process of new product development. This, along with ongoing developments in biological vectors and nanotechnology, has fueled market growth. Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association are involved in conducting trials by funding research institutes and pharmaceutical organizations and this is expected to significantly fuel sector growth. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce disease burden are attributive for industrial growth. Antisense and RNAi therapeutics services are applicable in treatment of a wide range of diseases that target nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production, thereby influencing industrial progress. Developments that involve the research of using different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth. However, challenges associated with drug delivery are expected to impede growth to a certain extent. Delivery technologies that enable mitigation of off-target effects and undesirable immunological stimulation need to be introduced in order to reduce the effect of restraining factors. Further key findings from the report suggest: • Antisense RNA technology accounted for the largest share in market revenue in 2017 owing to advantages associated with this technology over RNA interference • Based on the triggering of RNA molecules, this technology is segmented into siRNA and miRNA. Owing to significant involvement of miRNA in maintaining a cell's identity, these are used to provide deep insight to cancer metastasis • Usage of RNAi therapy to selectively target SNPs in genetic disorders is a major factor expected to provide this segment several potential treatment avenues over the forecast period • siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which enables it to emerge as the dominant sub-segment in oncology applications • Extensive R&D programs carried out to develop an efficient method for the delivery of RNA silencing therapeutic products is anticipated to propel growth. These R&D programs are based on obtaining desired pharmacological action prior to removal of the product from the cytoplasm and systemic circulation • Isis Pharmaceuticals/ Ionis Pharmaceuticals, GSK, Alnylam Pharmaceuticals, Marina Biosciences, Sanofi-Genzyme, Quark Pharmaceuticals, Gene Signal, and Benitec Biopharma are major companies in the market involved in development and commercialization of products • Strong product portfolio in different phases of clinical trials and preclinical development programs is expected to contribute to the growth of this industry.
Table of Contents
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 List of Data Sources
2.3 Information or Data Analysis
2.4 Market Formulation & Validation
Chapter 3 Antisense & RNAi Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Presence of strong pipeline product portfolio
3.1.1.2 Introduction of technological advancements in drug delivery
3.1.1.3 Implementation of favorable government initiatives & external funding for R&D exercises
3.1.1.4 Rising collaborations between pharmaceutical companies
3.1.2 Market restraint analysis
3.1.2.1 Expensive and tedious research programs
3.1.2.2 Delivery of RNAi therapeutics and off-target effects
3.2 Antisense & RNAi Therapeutics - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.3 Industry Analysis - Porter's
3.4 Penetration &Growth Prospect Mapping for Methods, 2017
3.5 Antisense & RNAi Therapeutics Ansoff Matrix, 2017
3.6 Antisense & RNAi therapeutics Pipeline Analysis
3.6.1 Olix Pharmaceuticals
3.6.2 Glaxo Smith Kline
3.6.3 Sanofi Aventis / Genzyme
3.6.4 Alnylam Pharmaceuticals
3.6.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals
3.6.6 Benitec Biopharma Ltd.
3.6.7 Arbutus Biopharma Ltd.
3.6.8 Silence Therapeutics
3.6.9 Bio-Path Holdings Inc.
3.6.10 Calando Pharmaceuticals
3.6.11 Gene Signal
3.6.12 iCo Therapeutics
3.6.13 Mirna Therapeutics/Synlogic
3.6.14 miRagen Therapeutics Inc.
3.6.15 Quark Pharmaceuticals
3.6.16 OncoGenex Pharmaceuticals Inc
3.6.17 Rexahn Pharmaceuticals
3.6.18 Biomarin/Prosensa
3.6.19 Regulus Therapeutics
3.6.20 Rxi Pharmaceuticals
3.6.21 Sarepta Therapeutics
3.6.22 Sylentis S.A.
3.6.23 Silenseed
3.6.24 Dicerna Pharmaceuticals
3.6.25 Santaris
3.6.26 Sirnaomics Inc.
Chapter 4 Antisense & RNAi Therapeutics Market Categorization: Technology Estimates & Trend Analysis
4.1 Antisense & RNAi Therapeutics Market: Technology Movement Analysis
4.2 RNA interference
4.2.1 RNA interference market, 2014 - 2025 (USD Million)
4.2.2 siRNA
4.2.2.1 siRNA market, 2014 - 2025 (USD Million)
4.2.3 miRNA
4.2.3.1 miRNA market, 2014 - 2025 (USD Million)
4.3 Antisense RNA
4.3.1 Antisense RNA market, 2014 - 2025 (USD Million)
Chapter 5 Antisense & RNAi Therapeutics Market Categorization: Application Estimates & Trend Analysis
5.1 Global Antisense & RNAi Therapeutics Market: Application Movement Analysis
5.2 Antisense & RNAi therapeutics in oncology
5.2.1 Oncology antisense RNA market, 2014 - 2025 (USD Million)
5.3 Antisense & RNAi therapeutics market in cardiovascular diseases
5.3.1 Cardiovascular antisense RNA market, 2014 - 2025 (USD Million)
5.4 Antisense & RNAi therapeutics market in respiratory disorders
5.4.1 Respiratory disorders antisense RNA market, 2014 - 2025 (USD Million)
5.5 Antisense & RNAi therapeutics market for renal diseases
5.5.1 Renal diseases antisense RNA market, 2014 - 2025 (USD Million)
5.6 Antisense & RNAi therapeutics market in neurodegenerative disorders
5.6.1 Neurodegenerative disorders antisense RNA market, 2014 - 2025 (USD Million)
5.7 Antisense & RNAi therapeutics market in genetic disorders
5.7.1 Genetic disorders antisense RNA market, 2014 - 2025 (USD Million)
5.8 Antisense & RNAi therapeutics market in infectious diseases
5.8.1 Infectious diseases antisense RNA market, 2014 - 2025 (USD Million)
5.9 Antisense & RNAi therapeutics market in other diseases
5.9.1 Other diseases antisense RNA market, 2014 - 2025 (USD Million)
Chapter 6 Antisense & RNAi Therapeutics Market Categorization: Route of Administration Estimates & Trend Analysis
6.1 Antisense & RNAi Therapeutics Market: Route of Administration Movement Analysis
6.2 Pulmonary delivery
6.2.1 Global pulmonary delivery market, 2014 - 2025 (USD Million)
6.3 Intravenous injections market
6.3.1 Global IV injections market, 2014 - 2025 (USD Million)
6.4 Intra-dermal injections
6.4.1 Global intra-dermal injections market, 2014 - 2025 (USD Million)
6.5 Intraperitoneal injections market
6.5.1 Global intra-peritoneal injections market, 2014 - 2025 (USD Million)
6.6 Topical delivery
6.6.1 Global topical delivery market, 2014 - 2025 (USD Million)
6.7 Other delivery
6.7.1 Global other delivery methods market, 2014 - 2025 (USD Million)
Chapter 7 Antisense & RNAi Therapeutics Market Categorization: Regional Estimates & Trend Analysis, by Application, & Route of Administration
7.1 Antisense & RNAi Therapeutics Market Share By Region, 2017 & 2025
7.2 North America
7.2.1 Antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
7.2.2 U.S.
7.2.2.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.2.2.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.2.2.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.2.3 Canada
7.2.3.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.2.3.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.2.3.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.3 Europe
7.3.1 Antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
7.3.2 Germany
7.3.2.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.3.2.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.3.2.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.3.3 U.K.
7.2.3.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.2.3.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.2.3.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.4 Asia Pacific
7.4.1 Antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
7.4.2 Japan
7.4.2.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.4.2.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.4.2.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.4.3 China
7.4.3.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.4.3.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.4.3.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.5 Latin America
7.5.1 Antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
7.5.2 Brazil
7.5.2.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.5.2.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.5.2.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
7.6 MEA
7.6.1 Antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
7.6.2 South Africa
7.6.2.1 Antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million)
7.6.2.2 Antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million)
7.6.2.3 Antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
Chapter 8 Competitive Landscape
8.1 Olix Pharmaceuticals
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 GlaxoSmithKline Plc
8.2.1 Company overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Sanofi S.A
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Alnylam Pharmaceuticals
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Ionis Pharmaceuticals
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Benitec Biopharma Ltd.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Acuitas Therapeutics
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.8 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Silence Therapeutics Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Enzon Pharmaceuticals Inc
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.11 Antisense Therapeutics Ltd.
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Bio-Path Holdings Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Product Benchmarking
8.12.4 Strategic Initiatives
8.13 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Gene Signal
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 Gradalis
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 iCo Therapeutics
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 Lorus Therapeutics (Aptose Biosciences)
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 Marina Biotech
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 miRagen Therapeutics
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives
8.20 Mirna Therapeutics Inc
8.20.1 Company Overview
8.20.2 Financial Performance
8.20.3 Product Benchmarking
8.20.4 Strategic Initiatives
8.21 OncoGeneX Pharmaceuticals
8.21.1 Company Overview
8.21.2 Financial Performance
8.21.3 Product Benchmarking
8.21.4 Strategic Initiatives
8.22 Quark Pharmaceuticals
8.22.1 Company Overview
8.22.2 Financial Performance
8.22.3 Product Benchmarking
8.22.4 Strategic Initiatives
8.23 Rexahn Pharmaceuticals
8.23.1 Company Overview
8.23.2 Financial Performance
8.23.3 Product Benchmarking
8.24 Regulus Therapeutics
8.24.1 Company Overview
8.24.2 Financial Performance
8.24.3 Product Benchmarking
8.25 Rxi Pharmaceuticals
8.25.1 Company Overview
8.25.2 Financial Performance
8.25.3 Strategic Initiatives
8.26 Santaris Pharma A/S (Roche)
8.26.1 Company Overview
8.26.2 Financial Performance
8.26.3 Strategic Initiatives
8.27 Sarepta Therapeutics
8.27.1 Company Overview
8.27.2 Financial Performance
8.27.3 Strategic Initiatives
8.28 Sirnaomics Inc.
8.28.1 Company Overview
8.28.2 Financial Performance
8.28.3 Strategic Initiatives
8.29 Dicerna Pharmaceuticals
8.29.1 Company Overview
8.29.2 Financial Performance
8.29.3 Strategic Initiatives
List of Tables TABLE 1 siRNA-based therapeutics in clinical trials with pulmonary route of administration TABLE 2 North America antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 3 North America RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 4 North America antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 5 North America antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 6 U.S. antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 7 U.S. RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 8 U.S. antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 9 U.S. antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 10 Canada antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 11 Canada RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 12 Canada antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 13 Canada antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 14 Europe antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 15 Europe RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 16 Europe antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 17 Europe antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 18 Germany antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 19 Germany RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 20 Germany antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 21 Germany antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 22 U.K. antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 23 U.K. RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 24 U.K. antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 25 U.K. antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 26 Asia Pacific antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 27 Asia Pacific RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 28 Asia Pacific antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 29 Asia Pacific antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 30 Japan antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 31 Japan RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 32 Japan antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 33 Japan antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 34 China antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 35 China RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 36 China antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 37 China antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 38 Latin America antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 39 Latin America RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 40 Latin America antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 41 Latin America antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 42 Brazil antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 43 Brazil RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 44 Brazil antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 45 Brazil antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 46 MEA antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 47 MEA RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 48 MEA antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 49 MEA antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE 50 South Africa antisense & RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 51 South Africa RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE 52 South Africa antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE 53 South Africa antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)
List of Figures FIG. 1 Market summary FIG. 2 Market research process FIG. 3 Information procurement FIG. 4 Primary research pattern FIG. 5 Market research approaches FIG. 6 Value chain based sizing & forecasting FIG. 7 QFD modelling for market share assessment FIG. 8 Market trends & outlook FIG. 9 Market segmentation & scope FIG. 10 Market driver relevance analysis (Current & future impact) FIG. 11 Market restraint relevance analysis (Current & future impact) FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological) FIG. 13 Porter's Five Forces Analysis FIG. 14 Penetration & growth prospect mapping for methods, 2017 FIG. 15 Antisense & RNAi Therapeutics Ansoff matrix, 2017 FIG. 16 Antisense & RNAi therapeutics market: Technology outlook key takeaways FIG. 17 Global antisense & RNAi therapeutics market: Technology movement analysis FIG. 18 RNA interference market, 2014 - 2025 (USD Million) FIG. 19 Global siRNA market, 2014 - 2025 (USD Million) FIG. 20 Global miRNA market, 2014 - 2025 (USD Million) FIG. 21 Global antisense RNA market, 2014 - 2025 (USD Million) FIG. 22 Antisense & RNAi therapeutics market: Application outlook key takeaways FIG. 23 Global antisense &RNAi therapeutics market: Application movement analysis FIG. 24 Global oncology antisense RNA market, 2014 - 2025 (USD Million) FIG. 25 Global cardiovascular antisense RNA market, 2014 - 2025 (USD Million) FIG. 26 Global respiratory disorders antisense RNA market, 2014 - 2025 (USD Million) FIG. 27 Global renal diseases antisense RNA market, 2014 - 2025 (USD Million) FIG. 28 Global neurodegenerative disorders antisense RNA market, 2014 - 2025 (USD Million) FIG. 29 Global genetic disorders antisense RNA market, 2014 - 2025 (USD Million) FIG. 30 Global infectious diseases antisense RNA market, 2014 - 2025 (USD Million) FIG. 31 Other diseases antisense RNA market, 2014 - 2025 (USD Million) FIG. 32 Antisense & RNAi therapeutics market: Route of administration outlook key takeaways FIG. 33 Global antisense & RNAi therapeutics market: Route of administration movement analysis FIG. 34 Global pulmonary delivery market, 2014 - 2025 (USD Million) FIG. 35 Global IV injections market, 2014 - 2025 (USD Million) FIG. 36 Global intra-dermal injections market, 2014 - 2025 (USD Million) FIG. 37 Global intra-peritoneal injections market, 2014 - 2025 (USD Million) FIG. 38 Global topical delivery market, 2014 - 2025 (USD Million) FIG. 39 Global other delivery methods market, 2014 - 2025 (USD Million) FIG. 40 Regional market place: Key takeaway FIG. 41 Antisense & RNAi therapeutics regional outlook, 2017 & 2025 FIG. 42 North America antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 43 U.S. antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 44 Canada antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 45 Europe antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 46 Germany antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 47 U.K. antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 48 Asia Pacific antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 49 Japan antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 50 China antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 51 Latin America antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 52 Brazil antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 53 MEA antisense & RNAi therapeutics market, 2014 - 2025 (USD Million) FIG. 54 Brazil antisense & RNAi therapeutics market, 2014 - 2025 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
